Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From hVIVO Plc
hVIVO's Andrew Catchpole On Human Challenge Studies, From COVID-19 To Malaria
hVIVO, a specialist contract research organization, performs human challenge trials, helping pharma companies develop vaccines with greater efficiency. Chief scientific officer Andrew Catchpole recently spoke with In Vivo about what it takes to perform an effective human challenge study, how they keep study participants safe, and how the company is helping address the ongoing scourge of malaria.
Australian Biotech Hopes Nasal Spray Can Alter Course Of COVID-19 Spread
ENA Respiratory expects its "preventive" nasal spray, which primes innate immunity against respiratory viruses including SARS-CoV-2, to play a meaningful role in protecting at-risk populations and lowering community transmission of COVID-19. It plans to explore the potential of the broad-spectrum antiviral immunomodulator in other areas, including COPD, and wider partnering opportunities.
ConserV Bioscience: Getting Ahead Of New COVID-19 Strains
The SEEK spin-out ConserV Bioscience is developing a broad-spectrum coronavirus vaccine, aiming to get ahead of the arrival of new strains of the virus.
Business and Technology Briefs
Brief summaries of recent product and company developments in the device industry, including a rift in the orthopedics industry following the DOJ settlement, new OTC aesthetics devices, and MannKind's prospects for partnering its inhaled insulin.
- Other Names / Subsidiaries
- Imutex Limited
- Open Orphan plc
- Retroscreen Virology Group plc
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.